Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy

Clinical Pharmacokinetics

Volumn 39, Issue 4, 2000, Pages 271-279

  Thalhammer, Florian ^a   Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MEROPENEM;

DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG URINE LEVEL; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW;

EID: 0033755078     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039040-00003     Document Type: Review

References (47)

1. Hellinger WC, Brewer NS. Carbapencms and monobactams: imipcnem, meropenem, and aztreonam. Mayo Clin Proc 1999; 74: 420-34
2. Moellering RC, Eliopoulos GM, Scntochnik DE. The carbapenems: new broad spectrum β-Iactam antibiotics. J Antimicrob Chemother 1989;24Suppl.A: 1-7
3. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 275-86
4. Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 1997; 24 Suppl. 2: S266-75
5. Harrison P, Moss SR, Featherstone A, et al. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989; 24 Suppl. A: 265-77
6. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995; Suppl. 96: 11-6
7. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24 (Suppl. A): 311-20
8. Nakashima M, Uematsu T, Janamaru M. Clinical phase I study of meropenem. Chemotherapy (Tokyo) 1992; 40 (Suppl. 1): 258-75
9. Leroy A, Fillastre JP, Borsa-Lebas F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992; 36: 2794-8
10. Cunha B A. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1999; 11: 167-77
11. Burman A, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J Antimicrob Chemother 1991; 27: 219-24
12. Tanimura M, Kataoka S, Yasuda M, et al. Basic and clinical studies of meropenem im urology. Chemotherapy (Tokyo) 1992; 40 Suppl. 1:258-75
13. Wise R, Logan M, Cooper M, et al. Meropenem pharmacokinetics and penetration into inflammatory exudate. Antimicrob Agents Chemother 1990; 34: 1515-7
14. Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995; 50: 73-101
15. Nix DE, Goodwin SD, Peloquin CA, et al. Antibiotic tissue penetration and ist relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemolher 1991;35: 1947-52
16. Christensson B A, Nilsson-Ehle M, Hutchison M, et al. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992; 36: 1532-7
17. Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32: 289-97
18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12
19. Soriano F. Optimal dosage of beta-lactam antibiotics: time above the MIC and inoculum effect. J Antimicrob Chemother 1992:30:566-9
20. Chimata M, Nagase M, Suzuki Y, et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993; 37: 229-33
21. Aoki N, Usuda Y, Koda Y, et al. Clinical pharmacology and efficacy of meropenem. Chemotherapy (Tokyo) 1992; 40 Suppl. 1:366-82
22. Ohkawa M, Tokunaga S, Hisazumi H. Effect of renal function on the pharmacokinetics of meropenem. Chemotherapy (Tokyo) 1992; 40 Suppl. 1:764-7
23. Leroy A, Fillastre JP, Etienne I, et al. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992; 42: 535-8
24. Thalhammer R Schmaldienst S, Elmenyawi I, et al. Multipledose pharmacokinetic of cefpirome in patients receiving chronic haemodialysis with high-flux membranes. Clin Pharmacol Ther 1996; 60: 645-50
25. Schmaldienst S, Traunmüller F, Burgmann H, et al. Multipledose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. Eur J Clin Pharmacol 2000 Apr; 56(1): 61-4
26. Schroeder TH, Krueger WA, Hansen M, et al. Elimination of meropenem by continuous hemo(dia)filtration: an in vitro one-compartment model. Int J Artif Organs 1999; 22:307-12
27. Giles LJ, Johnson Z, Phillips GJ, et al. Meropenem clearance by continuous haemofiltration: a comparison Of in vivo and in vitro data [abstract P68). Crit Care 1999; 3 Suppl. 1: 35
28. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42: 2417-20
29. Tegeder I, Neumann F, Bremer F, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65: 50-7
30. Meyer MM, Munar MY, Kohlhepp SJ, et al. Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis 1999; 33: 790-5
31. Krueger WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-4
32. Valtonen M, Tiula E, Backman JT, et al. Elimination of meropenem during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000; 45: 701-4
33. Giles J, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28: 632-7
34. Chan CY, Lai KN, Lam AW, et al. Pharmacokinetics of parenteral imipenem/cilastatin on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1991 ; 27: 225-32
35. Somani P, Freimer EH, Gross ML, et al. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimi-crob Agents Chemother 1988; 32: 530-4
36. Kropp H, Sundelof JG, Hajdu R, et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob Agents Chemother 1982; 22: 62-70
37. Norrby SR, Alestig K, Björnegård B, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother 1983; 23:3007
38. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136
39. Gibson TP, Demetriades JL, Bland JA. Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency. Am J Med 1985; 78 Suppl. 6A: 54-61
40. Pietroski NA, Graziani AL, Lawson LA, et al. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function. Antimicrob Agents Chemother 1991; 35: 972-5
41. Verbist L, Verpooten GA, Giuliano RA, et al. Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure. J Antimicrob Chemother 1986; 18 Suppl. E: 115-20
42. Kihara M, Ikeda Y, Shibata K, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol 1994; 42: 193-7
43. Konishi K, Suzuki H, Saruta T, et al. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimierob Agents Chemother 1991; 35: 1616-20
44. Berman SJ, Sugihara JG, Nakamura JM, et al. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. Am J Med 1985; 78 Suppl. 6A: 113-6
45. Hashimoto S, Honda M, Yamaguchi, et al. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill. ASAIO J 1997; 43: 84-8
46. Keller E, Fecht H, Böhler J, et al. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 1989; 4:640-5
47. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999; 31: 3-10